Invesaro

Stocks Comparison

Abbott Laboratories vs Bristol Myers Squibb: revenue, profit, margins and growth compared

Abbott Laboratories brought in $44.3B of revenue in fiscal 2025, Bristol Myers Squibb $48.2B in fiscal 2025. Revenue changed by +5.7% at Abbott Laboratories and -0.2% at Bristol Myers Squibb on the year before, so Abbott Laboratories grew faster. Abbott Laboratories kept 14.7% of its revenue as net profit, Bristol Myers Squibb 14.6%. Free cash flow was $7.4B at Abbott Laboratories and $12.8B at Bristol Myers Squibb.

Side by side, latest fiscal year

ABTBMY
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$44.3B$48.2B
Revenue growth+5.7%-0.2%
Net income$6.5B$7.1B
Net margin14.7%14.6%
Free cash flow$7.4B$12.8B
Free cash flow margin16.7%26.7%
Earnings per share (diluted)$3.72$3.46
Cash$8.5B$10.2B
Debt$12.9B$44.8B
Price to earnings27.218.2
Market value$175.3B$128.4B
Dividend yield2.37%3.96%
Rank by revenue in sector#18 of 523 · Health care#16 of 523 · Health care

Over the years

Revenue
ABT FY2018: $30.6BABT FY2019: $31.9BABT FY2020: $34.6BABT FY2021: $43.1BABT FY2022: $43.7BABT FY2023: $40.1BABT FY2024: $42BABT FY2025: $44.3BBMY FY2018: $22.6BBMY FY2019: $26.1BBMY FY2020: $42.5BBMY FY2021: $46.4BBMY FY2022: $46.2BBMY FY2023: $45BBMY FY2024: $48.3BBMY FY2025: $48.2BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $44.3BBMY $48.2B
Net income
ABT FY2018: $2.4BABT FY2019: $3.7BABT FY2020: $4.5BABT FY2021: $7.1BABT FY2022: $6.9BABT FY2023: $5.7BABT FY2024: $13.4BABT FY2025: $6.5BBMY FY2018: $4.9BBMY FY2019: $3.4BBMY FY2020: -$9BBMY FY2021: $7BBMY FY2022: $6.3BBMY FY2023: $8BBMY FY2024: -$8.9BBMY FY2025: $7.1BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $6.5BBMY $7.1B
Net margin
ABT FY2018: 7.7%ABT FY2019: 11.6%ABT FY2020: 13.0%ABT FY2021: 16.4%ABT FY2022: 15.9%ABT FY2023: 14.3%ABT FY2024: 31.9%ABT FY2025: 14.7%BMY FY2018: 21.8%BMY FY2019: 13.2%BMY FY2020: -21.2%BMY FY2021: 15.1%BMY FY2022: 13.7%BMY FY2023: 17.8%BMY FY2024: -18.5%BMY FY2025: 14.6%FY18FY19FY20FY21FY22FY23FY24FY25
ABT 14.7%BMY 14.6%
Revenue growth
ABT FY2019: +4.3%ABT FY2020: +8.5%ABT FY2021: +24.5%ABT FY2022: +1.3%ABT FY2023: -8.1%ABT FY2024: +4.6%ABT FY2025: +5.7%BMY FY2019: +15.9%BMY FY2020: +62.6%BMY FY2021: +9.1%BMY FY2022: -0.5%BMY FY2023: -2.5%BMY FY2024: +7.3%BMY FY2025: -0.2%FY19FY20FY21FY22FY23FY24FY25
ABT +5.7%BMY -0.2%
Free cash flow
ABT FY2018: $4.9BABT FY2019: $4.5BABT FY2020: $5.7BABT FY2021: $8.6BABT FY2022: $7.8BABT FY2023: $5.1BABT FY2024: $6.4BABT FY2025: $7.4BBMY FY2018: $6.1BBMY FY2019: $7.4BBMY FY2020: $13.3BBMY FY2021: $15.2BBMY FY2022: $11.9BBMY FY2023: $12.7BBMY FY2024: $13.9BBMY FY2025: $12.8BFY18FY19FY20FY21FY22FY23FY24FY25
ABT $7.4BBMY $12.8B

Fiscal years as each company reports them; the two may end in different months.

Questions about Abbott Laboratories and Bristol Myers Squibb

Which is bigger by revenue, Abbott Laboratories or Bristol Myers Squibb?

Bristol Myers Squibb is bigger by revenue: $48.2B in fiscal 2025, against $44.3B for Abbott Laboratories in fiscal 2025.

Which keeps more of its revenue as profit, Abbott Laboratories or Bristol Myers Squibb?

Abbott Laboratories had a net margin of 14.7% in fiscal 2025; Bristol Myers Squibb had 14.6% in fiscal 2025.

Which grew revenue faster, Abbott Laboratories or Bristol Myers Squibb?

In their latest fiscal years revenue changed by +5.7% at Abbott Laboratories and -0.2% at Bristol Myers Squibb.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies